Its potential for significant weight reduction over placebo makes it a promising candidate in the fight against obesity
Trulicity has been shown to reduce the risk of major cardiovascular events, making it a beneficial choice for patients with type 2 diabetes and cardiovascular risk factors
Left unchecked, MASH can evolve into cirrhosis, hepatic decompensation, and even hepatocellular carcinoma
Yes , as long as a doctor has approved treatment for you
Very common side effects (affecting more than 1 in 10 people) include: Nausea often the most troublesome symptom, particularly in the first few weeks Diarrhoea can range from mild to moderate in severity Common side effects (affecting up to 1 in 10 people) include: Vomiting may occur alongside nausea Constipation affects a significant proportion of users Abdominal pain or discomfort Decreased appetite whilst this contributes to weight loss, some patients find it excessive Dyspepsia (indigestion) Fatigue Injection site reactions such as redness, itching, or bruising These gastrointestinal symptoms typically arise because semaglutide slows gastric emptying, which is part of its therapeutic mechanism
